This site is intended for healthcare professionals
Journals
  • Home
  • /
  • Journals
  • /
  • Asthma
  • /
  • The safety of mepolizumab for the treatment of ast...
Journal

The safety of mepolizumab for the treatment of asthma.

Read time: 1 mins
Published:1st Mar 2017
Author: Leung E, Al Efraij K, FitzGerald JM.
Availability: Pay for access, or by subscription
Ref.:Expert Opin Drug Saf. 2017;16(3):397-404.
DOI:10.1080/14740338.2017.1286327

Introduction: Asthma is an airway disease characterized by airway inflammation. It is associated with significant morbidity, mortality, and costs to the healthcare system and society. Interleukin-5 (IL-5) was identified for its role in eosinophil development, maturation, and survival in tissues, which has been related to disease severity and airway eosinophilia.

Areas covered: In this review, we will present the pharmacokinetics and dynamics of mepolizumab in addition to efficacy and safety data.

Expert Opinion: Mepolizumab is novel, new, first-in-class therapy targeting IL-5. It has been found to be particularly effective in the management of patients with asthma whose peripheral blood eosinophil count is at a well-defined cut point within the normative range. This easily available biomarker, along with a history of asthma exacerbations, has translated into a clinically significant reduction in asthma exacerbations and the dose of oral corticosteroids in patients who previously have been prednisone-dependent. The pivotal studies indicate that mepolizumab was well tolerated, with the most frequently reported adverse events being headache, nasopharyngitis, worsening of asthma, and local injection reactions. These study investigators did not report any deaths or anaphylaxis related to mepolizumab.

 

Read abstract on library site

Access full article